Sequana Medical – executive interview

Published on 28 July 2021

Sequana Medical is a Belgian commercial-stage medical device company that uses its proprietary alfapump and Direct Sodium Removal (DSR) technologies to develop innovative treatments for diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure. The alfapump is CE marked for refractory ascites and is in a pivotal North American study covering this indication.

In this interview, chief executive officer Ian Crosbie describes the commercial opportunities for the alfapump and DSR platforms in areas of unmet medical need, highlights the company’s recent activities and clinical results and provides an overview of key upcoming catalysts and milestones.

Share this with friends and colleagues